EMBECTA CORP. Operating Cash Flow
EMBECTA CORP. (EMBC) reported Operating Cash Flow of $90.10 million for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-07
- EMBECTA CORP. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $41.80M, a 48.52% decline year-over-year.
- EMBECTA CORP. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was $31.10M, a 2.20% decline year-over-year.
- EMBECTA CORP. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was $17.20M.
- EMBECTA CORP. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was $84.00M, a 215.79% increase year-over-year.
- EMBECTA CORP. net cash provided by (used in) operating activities for fiscal 2025 was $191.70M, a 436.97% increase from fiscal 2024.
- EMBECTA CORP. net cash provided by (used in) operating activities for fiscal 2024 was $35.70M, a 47.27% decline from fiscal 2023.
- EMBECTA CORP. net cash provided by (used in) operating activities for fiscal 2023 was $67.70M, a 83.58% decline from fiscal 2022.
- EMBECTA CORP. net cash provided by (used in) operating activities for fiscal 2022 was $412.20M, a 9.66% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $41.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-07 | $72.90M derived: sum of 2 quarters · filed 2026-08-07 | $90.10M 10-Q · filed 2026-08-07 | $174.10M derived: sum of 4 quarters · filed 2026-08-07 |
| 2026-03-31 | $31.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-05 | $48.30M 10-Q · filed 2026-05-05 | $132.30M derived: sum of 3 quarters · filed 2026-05-05 | $213.50M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-12-31 | $17.20M 10-Q · filed 2026-02-05 | $101.20M derived: sum of 2 quarters · filed 2026-02-05 | $182.40M derived: sum of 3 quarters · filed 2026-08-07 | $214.20M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-09-30 | $84.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $165.20M derived: sum of 2 quarters · filed 2026-08-07 | $197.00M derived: sum of 3 quarters · filed 2026-08-07 | $191.70M 10-K · filed 2025-11-25 |
| 2025-06-30 | $81.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2026-08-07 | $113.00M derived: sum of 2 quarters · filed 2026-08-07 | $107.70M 10-Q · filed 2026-08-07 | $134.30M derived: sum of 4 quarters · filed 2026-08-07 |
| 2025-03-31 | $31.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-05-05 | $26.50M 10-Q · filed 2026-05-05 | $53.10M derived: sum of 3 quarters · filed 2026-05-05 | $51.00M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | -$5.30M 10-Q · filed 2026-02-05 | $21.30M derived: sum of 2 quarters · filed 2026-02-05 | $19.20M derived: sum of 3 quarters · filed 2026-02-05 | $43.50M derived: sum of 4 quarters · filed 2026-02-05 |
| 2024-09-30 | $26.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $24.50M derived: sum of 2 quarters · filed 2025-11-25 | $48.80M derived: sum of 3 quarters · filed 2025-11-25 | $35.70M 10-K · filed 2025-11-25 |
| 2024-06-30 | -$2.10M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-08-08 | $22.20M derived: sum of 2 quarters · filed 2025-08-08 | $9.10M 10-Q · filed 2025-08-08 | $38.70M derived: sum of 4 quarters · filed 2025-11-25 |
| 2024-03-31 | $24.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-05-09 | $11.20M 10-Q · filed 2025-05-09 | $40.80M derived: sum of 3 quarters · filed 2025-11-25 | $31.50M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-12-31 | -$13.10M 10-Q · filed 2025-02-06 | $16.50M derived: sum of 2 quarters · filed 2025-11-25 | $7.20M derived: sum of 3 quarters · filed 2025-11-25 | -$5.80M derived: sum of 4 quarters · filed 2025-11-25 |
| 2023-09-30 | $29.60M derived: 10-K 12 month − 10-Q 9 month · filed 2025-11-25 | $20.30M derived: sum of 2 quarters · filed 2025-11-25 | $7.30M derived: sum of 3 quarters · filed 2025-11-25 | $67.70M 10-K · filed 2025-11-25 |
| 2023-06-30 | -$9.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-08-09 | -$22.30M derived: sum of 2 quarters · filed 2024-08-09 | $38.10M 10-Q · filed 2024-08-09 | $96.10M derived: sum of 4 quarters · filed 2024-12-11 |
| 2023-03-31 | -$13.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-05-09 | $47.40M 10-Q · filed 2024-05-09 | $105.40M derived: sum of 3 quarters · filed 2024-12-11 | $138.20M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-12-31 | $60.40M 10-Q · filed 2024-02-09 | $118.40M derived: sum of 2 quarters · filed 2024-12-11 | $151.20M derived: sum of 3 quarters · filed 2024-12-11 | $333.80M derived: sum of 4 quarters · filed 2024-12-11 |
| 2022-09-30 | $58.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-11 | $90.80M derived: sum of 2 quarters · filed 2024-12-11 | $273.40M derived: sum of 3 quarters · filed 2024-12-11 | $412.20M 10-K · filed 2024-12-11 |
| 2022-06-30 | $32.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-08-08 | $215.40M derived: sum of 2 quarters · filed 2023-08-08 | $354.20M 10-Q · filed 2023-08-08 | $439.70M derived: sum of 4 quarters · filed 2023-11-29 |
| 2022-03-31 | $182.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-05-12 | $321.40M 10-Q · filed 2023-05-12 | $406.90M derived: sum of 3 quarters · filed 2023-11-29 | $536.60M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-12-31 | $138.80M 10-Q · filed 2023-02-14 | $224.30M derived: sum of 2 quarters · filed 2023-11-29 | $354.00M derived: sum of 3 quarters · filed 2023-11-29 | $473.70M derived: sum of 4 quarters · filed 2023-11-29 |
| 2021-09-30 | $85.50M derived: 10-K 12 month − 10-Q 9 month · filed 2023-11-29 | $215.20M derived: sum of 2 quarters · filed 2023-11-29 | $334.90M derived: sum of 3 quarters · filed 2023-11-29 | $456.30M 10-K · filed 2023-11-29 |
| 2021-06-30 | $129.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-08-15 | $249.40M derived: sum of 2 quarters · filed 2022-08-15 | $370.80M 10-Q · filed 2022-08-15 | |
| 2021-03-31 | $119.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-05-13 | $241.10M 10-Q · filed 2022-05-13 | ||
| 2020-12-31 | $121.40M 10-Q · filed 2022-03-16 | |||
| 2020-09-30 | $498.50M 10-K · filed 2022-12-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |